Search
Susoctocog alfa
go.drugbank.com/drugs/DB11606ApprovedInvestigationalIn a global, prospective, controlled, multi-center Phase 2/3 open-label clinical trial, all patients responded to susoctocog alfa treatment within 24 hours [L1129].
Cyclopentamine
go.drugbank.com/drugs/DB08999ApprovedWithdrawnCyclopentamine was an over the counter treatment for nasal congestion in Europe and Australia.
Pracinostat
go.drugbank.com/drugs/DB05223InvestigationalPracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing. Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with...
Hexobarbital
go.drugbank.com/drugs/DB01355ExperimentalA barbiturate that is effective as a hypnotic and sedative.
Pegsitacianine
go.drugbank.com/drugs/DB19098InvestigationalPegsitacianine is under investigation in clinical trial NCT05576974 (A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence
Carbocisteine
go.drugbank.com/drugs/DB04339ApprovedInvestigational[A230993] Carbocisteine is currently not FDA or Health Canada approved, but is approved for use in Asia, Europe, and South America.
Products: MADECASOL NRezafungin
go.drugbank.com/drugs/DB16310ApprovedInvestigational[L45633,L45658] It was subsequently approved in the EU in November of the same year. [L52745] … [A258403] In March 2023, the FDA approved rezafungin for injection for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.
Synonyms: Echinocandin B, 1-((4R,5R)-4-hydroxy-N2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-5-(2-(trimethylammonio)ethoxy)-l-ornithine)-4-((4S)-4-hydroxy-4-(4-hydroxyphenyl)-l-allothreonine)-Etoperidone
go.drugbank.com/drugs/DB09194ApprovedWithdrawnEtoperidone is an atypical antidepressant introduced in Europe in 1977.
Cerliponase alfa
go.drugbank.com/drugs/DB13173ApprovedInvestigationalCerliponase alfa is a hydrolytic lysosomal N-terminal tripeptidyl peptidase-1 (TPP1).
Categories: Hydrolytic Lysosomal N-terminal Tripeptidyl PeptidaseNirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigationalL46921] Paxlovid was approved for use in Canada in January 2022 for the treatment of adult patients with mild-moderate COVID-19 [L39544] and later granted conditional marketing authorization by the European